HILLSTREAM BIOPHARMA INC (HILS) Stock Price, Quote, News and Overview
NASDAQ:HILS - Nasdaq - US4327051011 - Common Stock - Currency: USD
HILS Quote, Performance and Key Statistics
0.2305
+0.01 (+2.76%)
The current stock price of HILS is 0.2305 USD. In the past month the price decreased by -4.75%. In the past year, price decreased by -70.5%.
HILS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About HILS
Company Profile
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.
Company Info
HILLSTREAM BIOPHARMA INC
1200 Route 22 East, Suite 2000
Bridgewater NEW JERSEY US
Employees: 1
Company Website: https://hillstreambio.com/
Phone: 19089553140.0
HILLSTREAM BIOPHARMA INC / HILS FAQ
What is the stock price of HILLSTREAM BIOPHARMA INC today?
The current stock price of HILS is 0.2305 USD. The price increased by 2.76% in the last trading session.
What is the ticker symbol for HILLSTREAM BIOPHARMA INC stock?
The exchange symbol of HILLSTREAM BIOPHARMA INC is HILS and it is listed on the Nasdaq exchange.
On which exchange is HILS stock listed?
HILS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HILLSTREAM BIOPHARMA INC stock?
6 analysts have analysed HILS and the average price target is 4.08 USD. This implies a price increase of 1670.07% is expected in the next year compared to the current price of 0.2305. Check the HILLSTREAM BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HILLSTREAM BIOPHARMA INC worth?
HILLSTREAM BIOPHARMA INC (HILS) has a market capitalization of 3.88M USD. This makes HILS a Nano Cap stock.
How many employees does HILLSTREAM BIOPHARMA INC have?
HILLSTREAM BIOPHARMA INC (HILS) currently has 1 employees.
What are the support and resistance levels for HILLSTREAM BIOPHARMA INC (HILS) stock?
HILLSTREAM BIOPHARMA INC (HILS) has a resistance level at 0.24. Check the full technical report for a detailed analysis of HILS support and resistance levels.
Should I buy HILLSTREAM BIOPHARMA INC (HILS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HILS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HILS, evaluating the profitability, health, valuation and growth aspects
- HILLSTREAM BIOPHARMA INC (HILS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HILLSTREAM BIOPHARMA INC (HILS) Sales and EPS estimates to see what analysts future expectations are.
- HILLSTREAM BIOPHARMA INC (HILS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HILLSTREAM BIOPHARMA INC (HILS) Insider and Institutional Ownership to learn about the owners and their transactions.
- HILLSTREAM BIOPHARMA INC (HILS) Stock Chart to make your own analysis
- HILLSTREAM BIOPHARMA INC (HILS) Latest news and press-releases to stay up to date.
Does HILLSTREAM BIOPHARMA INC (HILS) stock pay dividends?
HILS does not pay a dividend.
When does HILLSTREAM BIOPHARMA INC (HILS) report earnings?
HILLSTREAM BIOPHARMA INC (HILS) will report earnings on 2023-11-06.
What is the Price/Earnings (PE) ratio of HILLSTREAM BIOPHARMA INC (HILS)?
HILLSTREAM BIOPHARMA INC (HILS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
HILS Technical Analysis
HILS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HILS. HILS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
HILS Financial Highlights
Over the last trailing twelve months HILS reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS decreased by -160.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
HILS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to HILS. The Buy consensus is the average rating of analysts ratings from 6 analysts.